Followers | 1078 |
Posts | 80327 |
Boards Moderated | 8 |
Alias Born | 03/10/2009 |
Monday, January 11, 2021 8:32:03 AM
01/11/2021 | 08:30am EST
share with twitter
share with LinkedIn
share with facebook
Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million. The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer.
In consideration for granting the license, Silo Pharma received a one-time cash payment of $500,000 and shares of newly designated Convertible Preferred Stock valued at $500,000 on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) in the event that the licensed property is commercially developed.
“Our Agreement advances Silo Pharma’s unique approach to researching and discovering therapeutics that can be used in combination with psychedelic elements” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are enthusiastic about this agreement and opportunity. Researching the use of psilocybin to treat both cancer and cancer side effects is a noteworthy opportunity for Silo Pharma and its shareholders. We look forward to updating investors on this agreement and further developments.”
Further information regarding the Agreement can be found in the Company’s Form 8-K filed with the SEC on January 11, 2021.
About Silo Pharma
Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com.
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Company Contact: Investor Relations Contact:
Silo Pharma, Inc.
Eric Weisblum, CEO
Email: eric@silopharma.com Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent SILO News
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment • GlobeNewswire Inc. • 04/23/2024 12:15:00 PM
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic • GlobeNewswire Inc. • 04/10/2024 12:11:00 PM
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic • GlobeNewswire Inc. • 03/20/2024 12:30:00 PM
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain • GlobeNewswire Inc. • 03/18/2024 11:15:00 AM
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD • GlobeNewswire Inc. • 02/28/2024 01:25:00 PM
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery • GlobeNewswire Inc. • 02/14/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 06:15:35 PM
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology • GlobeNewswire Inc. • 02/01/2024 03:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/31/2024 05:15:16 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:29:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:27:04 PM
- Silo Pharma Announces Positive Results in Alzheimer’s Disease Study • GlobeNewswire Inc. • 01/24/2024 01:55:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/23/2024 10:01:06 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/11/2024 05:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:30:11 PM
- Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD • GlobeNewswire Inc. • 01/04/2024 01:55:00 PM
- Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia • GlobeNewswire Inc. • 12/28/2023 01:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:13:38 PM
- Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b) • Edgar (US Regulatory) • 12/20/2023 09:58:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:44:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 11:13:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:05:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:55:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 02:10:20 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM